A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects.
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study was a randomized, double-blind, placebo-controlled phase I clinical trial of AP026
(TQA2226) for injection in adult healthy subjects, which planned to recruit 74 healthy
subjects. The main purpose was to evaluate the safety and tolerance of AP026 (TQA2226) for
injection after single and multiple doses in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.